Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development
The 31‑patient BEACON trial met key efficacy measures with no serious adverse events, positioning the oral TYK2/JAK1 inhibitor for a Phase 3 start in 2026 pending FDA input.
